CR CRM Salesforce, Inc. 로딩 중... : 애널리스트의 강세 및 약세 의견

Veeva's commercial cross-sell is succeeding: it has 10 of 16 top-20 CRM migration wins, with win rates above 80%, and close to 40 successful migrations. — This is direct, quantifiable share gain against Salesforce in the most valuable pharmaceutical CRM accounts, signaling continued erosion of Salesforce's Life Sciences footprint.

Veeva is accelerating the end-of-support date for its legacy CRM product by 9 months to December 2029, signaling faster-than-expected industry migration and stronger Vault CRM traction. — A faster end-of-support deadline will force more Salesforce CRM users to make migration decisions sooner, potentially accelerating Veeva's market share gains and impacting Salesforce's remaining pharma CRM revenue.

Veeva says customers are beginning to see 'compounding' value from cross-X as digital marketing spend grows, particularly with new digital channels. — This suggests increased demand for ad-tech and analytics platforms that can measure digital pharma marketing, benefiting Google's ad network and potentially pressuring traditional media.